24.18

0.37% -0.09

After Hours: 24.18

iShares Genomics Immunology and Healthcare ETF (IDNA)

Overview News Price History Option Chain Discussions Forecast Dividend History

iShares Genomics Immunology and Healthcare ETF stock is currently priced at $24.18, with a 24-hour trading volume of 27,998. It has seen a -0.37% decreased in the last 24 hours and a +9.46% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $24.20 pivot point. If it approaches the $24.10 support level, significant changes may occur.

Previous Close:

$24.27

Open:

$24.28

24h Volume:

27,998

Market Cap:

$N/A

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+4.09%

1M Performance:

+9.46%

6M Performance:

+20.42%

1Y Performance:

+0.12%

1D Range:

$24.11

$24.30

52W Range:

$17.33

$25.52

iShares Genomics Immunology and Healthcare ETF Stock (IDNA) Company Profile

Name

iShares Genomics Immunology and Healthcare ETF

Sector

Financial (4627)

Industry

Exchange Traded Fund (3096)

Phone

1-800-474-2737

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

IDNA's Discussions on Twitter

iShares Genomics Immunology and Healthcare ETF Stock (IDNA) Latest News

IDNA ETF: Continues To Underperform, But With Long Run Potential - Seeking Alpha

Seeking Alpha

Megatrends: Gene Therapy and Editing | Investing | U.S. News - U.S News & World Report Money

U.S News & World Report Money

iShares Genomics Immunology and Healthcare ETF Stock (IDNA) Financials Data

There is no financial data for iShares Genomics Immunology and Healthcare ETF (IDNA). Check out other stocks for more information.

The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.